HTGC - Hercules Capital, Inc.

NYSE - NYSE Delayed Price. Currency in USD
13.47
+0.02 (+0.15%)
At close: 4:02PM EDT

13.65 +0.18 (1.34%)
After hours: 6:45PM EDT

Stock chart is not supported by your current browser
Previous Close13.45
Open13.50
Bid0.00 x 1100
Ask13.80 x 1800
Day's Range13.40 - 13.56
52 Week Range11.55 - 13.97
Volume627,296
Avg. Volume494,020
Market Cap1.268B
Beta0.73
PE Ratio (TTM)12.47
EPS (TTM)1.08
Earnings DateAug 2, 2018
Forward Dividend & Yield1.24 (9.63%)
Ex-Dividend Date2018-05-11
1y Target Est14.41
Trade prices are not sourced from all markets
  • Business Wire8 days ago

    Hercules Announces Date for Release of Second Quarter 2018 Financial Results and Conference Call

    Hercules Capital, Inc. , the leading specialty finance company to innovative, venture growth, pre-IPO and M&A stage companies backed by leading venture capital firms, today announced that it has scheduled its second quarter 2018 financial results conference call for Thursday, August 2, 2018, at 2:00 p.m.

  • Business Wire9 days ago

    Hercules Capital Proudly Announces Eight Portfolio Companies Have Completed or Announced an IPO or M&A Liquidity Event Year-to-Date 2018

    PALO ALTO, Calif.-- -- Hercules’ Leading Originations Platform Continues to Finance Some of the Most Promising Innovative and Disruptive Venture-Backed Companies in the Market Hercules Capital, Inc. , the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, is pleased to announce the latest liquidity events for eight of its portfolio ...

  • GlobeNewswire11 days ago

    Acacia Pharma Provides Operating Update for the First Half 2018

     Cambridge, UK and Indianapolis, US - 9 July 2018: Acacia Pharma Group plc ("Acacia Pharma", the "Company" or the "Group"), (ACPH.BR) provides an unaudited operating update for the first half 2018 (six months ended 30 June 2018). Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients targeting a specific unmet need to improve patient outcomes and lower hospital costs. Dr Julian Gilbert, CEO of Acacia Pharma, commented: "The Group has made important progress during the first half 2018 preparing for the launch, if approved, of BARHEMSYS(TM) for the treatment and prevention of post-operative nausea & vomiting (PONV) in surgical patients.

  • Thomson Reuters StreetEvents15 days ago

    Edited Transcript of HTGC earnings conference call or presentation 3-May-18 9:00pm GMT

    Q1 2018 Hercules Capital Inc Earnings Call

  • PR Newswire17 days ago

    Merrimack Secures $25 Million Debt Facility with Hercules Capital

    CAMBRIDGE, Mass., July 2, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the closing of a $25 million term loan with Hercules Capital (HTGC), $15 million of which was funded at closing today. Merrimack's current cash and cash equivalents, including the $15 million of loan proceeds received, and certain potential net milestone payments anticipated from Shire are projected to fund the company's planned operations into the first quarter of 2020. "This non-dilutive financing strengthens Merrimack's financial position, allowing us to remain focused on advancing the discovery, clinical and business development efforts for our nine wholly-owned programs in development, including our two clinical readouts expected later this year from MM-121 and MM-310," said Richard Peters, M.D., Ph.D., President and Chief Executive Officer of Merrimack.

  • GlobeNewswire18 days ago

    Acacia Pharma Secures $30 Million Credit Facility with Hercules Technology Growth Capital to Support Intended Commercialisation of BARHEMSYS(TM) for Post-operative Nausea & Vomiting in the US

    Cambridge, UK and Indianapolis, US - 2 July 2018: Acacia Pharma Group plc ("Acacia Pharma", the "Company" or the "Group"), (ACPH.BR), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, has secured a credit facility of up to $30 million with Hercules Technology Growth Capital, Inc. ("Hercules") (HTGC) to support the intended US launch of intravenous amisulpride for the treatment and prevention of post-operative nausea & vomiting (PONV), which is expected to be launched under the tradename BARHEMSYS(TM) following the conditional approval by the US Food & Drug Administration. As previously announced, the target PDUFA date for BARHEMSYS is 5 October 2018.

  • Is It Time To Buy Hercules Capital Inc (NYSE:HTGC)?
    Simply Wall St.27 days ago

    Is It Time To Buy Hercules Capital Inc (NYSE:HTGC)?

    Hercules Capital Inc (NYSE:HTGC), a capital markets company based in United States, maintained its current share price over the past couple of month on the NYSE, with a relatively tightRead More...

  • Business Wirelast month

    Hercules Capital, Inc. Closes Public Offering of Common Stock Including Option to Purchase Additional Shares

    Hercules Capital, Inc. (HTGC) (“Hercules”) today announced that it has closed its underwritten public offering of 6,000,000 shares of its common stock. In addition, the underwriters fully exercised their over-allotment option to purchase 900,000 additional shares of Hercules’ common stock. The underwriters purchased the shares of common stock from Hercules for a price of $11.78 per share, and net proceeds from the offering after deducting estimated offering expenses payable by the Company are expected to be approximately $81.0 million.

  • Business Wirelast month

    Hercules’ Highly Asset Sensitive Debt Investment Portfolio to Generate Additional $0.04 of Net Investment Income Earnings Annually(2) From the Recent Increase in the Federal Reserve Benchmark Interest Rate

    Hercules Capital, Inc. , the leading specialty finance company to innovative, venture growth, pre-IPO and M&A stage companies backed by leading venture capital firms, today announced the estimated accretive impact to its debt investment portfolio attributed to the Federal Reserve - Federal Open Market Committee’s increase in the federal funds rate by 25 basis points, or 0.25%.

  • Business Wirelast month

    Hercules Capital, Inc. Prices Public Offering of Common Stock

    Hercules Capital, Inc. (HTGC) (“Hercules”) today announced that it has priced its public offering of 6,000,000 shares of its common stock at a public offering price of $12.15 per share for total gross proceeds of approximately $72.9 million. Hercules has also granted the underwriters an option to purchase up to an additional 900,000 shares of its common stock. Wells Fargo Securities, Morgan Stanley, Jefferies LLC, and Keefe, Bruyette & Woods, A Stifel Company, are acting as joint book-running managers in this offering, and Compass Point is acting as lead manager in this offering.

  • Business Wirelast month

    Hercules Capital, Inc. Announces Public Offering of Common Stock

    Hercules Capital, Inc. (HTGC) (“Hercules”) today announced that it plans to make a public offering of 6,000,000 shares of its common stock. Hercules also plans to grant the underwriters for the offering an option to purchase up to an additional 900,000 shares of its common stock. Wells Fargo Securities, Morgan Stanley, Jefferies LLC, and Keefe, Bruyette & Woods, A Stifel Company, are acting as joint book-running managers in this offering, and Compass Point is acting as lead manager in this offering.

  • Business Wirelast month

    Hercules Capital on Pace to Potentially Exceed $1.0 Billion in Total New Debt and Equity Commitments in 2018

    Hercules Capital, Inc. (HTGC) (“Hercules” or the “Company”), the leading and largest specialty finance company specifically focused on providing growth capital to some of the most innovative and disruptive venture capital backed growth companies in the U.S., many of which are pre-IPO and M&A stage companies backed by some of the leading top tier venture capital firms, today provided an intra-quarter business update for the second quarter and year-to-date outlook for 2018. “We are off to a tremendous start for 2018 and well positioned to achieve another record year with nearly $580 million in closed new debt and equity commitments to date,” stated Manuel A. Henriquez, founder, chairman and chief executive officer of Hercules.

  • Business Wirelast month

    Hercules Capital Forms New SaaS Finance Group – Hercules Capital SaaS Finance Division

    Hercules Capital, Inc. , the leading specialty finance company to innovative venture growth, pre-IPO and M&A stage companies backed by leading venture capital firms, today announced the official launch of the Hercules Capital SaaS Finance division, which will be dedicated exclusively to servicing the needs of fast growing SaaS companies in this specialized and growing technology vertical.

  • Seeking trifecta against kidney disease, biotech team lines up $150 million IPO
    American City Business Journalslast month

    Seeking trifecta against kidney disease, biotech team lines up $150 million IPO

    They built and sold Ilypsa and Relypsa, now this team is prepping their latest company to ask the FDA to approve another drug for chronic kidney disease patients.

  • Business Wire2 months ago

    Hercules Increases Its Union Bank Credit Facility to $100.0 Million to Support Investment Portfolio Growth

    Hercules Capital, Inc. (HTGC) (“Hercules” or the “Company”) the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, today announced that effective May 25, 2018, it has increased its credit facility with MUFG Union Bank, N.A. (“the Union Bank Credit Facility”), under which MUFG Union Bank has committed an additional $25.0 million pursuant to a $125.0 million accordion feature, for a total of $100.0 million in credit capacity (subject to borrowing base, leverage and other restrictions). Borrowings under the facility maintain the current interest rate of LIBOR (with a floor of 0%) plus 3.25% and a maturity date of May 2020, with a 12-month amortization period.

  • Does Hercules Capital Inc’s (NYSE:HTGC) Recent Track Record Look Strong?
    Simply Wall St.2 months ago

    Does Hercules Capital Inc’s (NYSE:HTGC) Recent Track Record Look Strong?

    After looking at Hercules Capital Inc’s (NYSE:HTGC) latest earnings announcement (31 March 2018), I found it useful to revisit the company’s performance in the past couple of years and assessRead More...

  • May Top Value-Adding Stocks
    Simply Wall St.2 months ago

    May Top Value-Adding Stocks

    Are you an investor looking for high-growth, steady income, or both? What makes a suitable investment stock for your personal needs? Given that there are many factors to consider, I’veRead More...

  • Business Wire2 months ago

    Hercules Announces Upcoming Events for Financial Community

    Hercules Capital, Inc. , the leading specialty financing provider to innovative venture growth, pre-IPO and M&A stage companies backed by leading ventu

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in The AES, Immune Pharmaceuticals, Hercules Capital, Zendesk, Chevron, and Cornerstone OnDemand — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, May 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The ...

  • Associated Press3 months ago

    Hercules Tech: 1Q Earnings Snapshot

    The Palo Alto, California-based company said it had net income of 7 cents per share. Earnings, adjusted for investment costs, came to 31 cents per share. The results surpassed Wall Street expectations. ...

  • Business Wire3 months ago

    Hercules Capital Announces First Quarter 2018 Financial Results and Quarterly Distribution of $0.31 per Share

    Hercules Capital, Inc. , the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, today announced its financial results for the first quarter ended March 31, 2018.

  • GlobeNewswire3 months ago

    RumbleOn Announces Closing of $15 Million Senior Secured Credit Facility With Hercules Capital, Inc.

    RumbleOn, Inc. (RMBL), a disruptive e-commerce platform facilitating, in one online location, the ability of consumers and dealers to buy, sell, trade, and finance pre-owned vehicles with an emphasis on motorcycles and other powersports, today announced it has entered into a $15 million Senior Secured Credit Facility with Hercules Capital, Inc. (“Hercules”), a leader in customized debt financing for companies in technology and life sciences related markets.   Under the terms of the facility, $5.0 million will be funded at closing with the balance available in two additional tranches over the term of the facility, subject to certain operating targets. Pursuant to the loan agreement, RumbleOn issued to Hercules at closing a warrant to purchase 81,818 shares of RumbleOn Class B common stock at an exercise price of $5.50 per share.

  • Business Wire3 months ago

    Hercules Capital Closes Public Offering of $75.0 Million 5.25% Notes Due 2025

    Hercules Capital, Inc. (HTGC) (“Hercules” or the “Company”), today announced that it has closed an underwritten public offering of $75.0 million in aggregate principal amount of 5.25% notes due 2025 (the “Notes”). The Notes will mature on April 30, 2025, and may be redeemed in whole or in part at any time or from time to time at the Company’s option on or after April 30, 2021. The Company intends to apply to list the Notes on the New York Stock Exchange under the trading symbol “HCXZ.” The Company has also granted the underwriters a 30-day option to purchase up to an additional $11,250,000 in aggregate principal amount of the Notes to cover over-allotments, if any.

  • Why Hercules Capital Inc (NYSE:HTGC) Could Be A Buy
    Simply Wall St.3 months ago

    Why Hercules Capital Inc (NYSE:HTGC) Could Be A Buy

    Hercules Capital Inc (NYSE:HTGC), a capital markets company based in United States, received a lot of attention from a substantial price movement on the NYSE over the last few months,Read More...

  • Business Wire3 months ago

    Hercules Capital Prices Public Offering of $75.0 Million 5.25% Notes due 2025

    Hercules Capital, Inc. , today announced that it has priced an underwritten public offering of $75.0 million in aggregate principal amount of 5.25% notes due 2025 .